Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2023

Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2023


Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Highlights

The global Duchenne Muscular Dystrophy (DMD) Therapeutics market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights


In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals

Product Type Insights

Global markets are presented by Duchenne Muscular Dystrophy (DMD) Therapeutics type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Duchenne Muscular Dystrophy (DMD) Therapeutics are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Duchenne Muscular Dystrophy (DMD) Therapeutics segment by Type

Exondys
Emflaza
Translarna

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Duchenne Muscular Dystrophy (DMD) Therapeutics market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application

Hospitals
Clinics
Home Care

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Duchenne Muscular Dystrophy (DMD) Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy (DMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Duchenne Muscular Dystrophy (DMD) Therapeutics industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Hospitals
2.3.3 Clinics
2.3.4 Home Care
2.4 Assumptions and Limitations
3 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2018-2023)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2023-2028)
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2018-2023)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2018-2029)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
5.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2018-2023)
5.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2024-2029)
5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
5.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
5.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
5.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
5.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
6.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2018-2023)
6.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2018-2023)
6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head office and Area Served
6.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players, Product Type & Application
6.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players, Date of Enter into This Industry
6.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2018-2029)
7.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023)
7.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2018-2029)
8.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023)
8.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2018-2029)
9.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023)
9.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2018-2029)
10.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023)
10.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2018-2029)
11.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023)
11.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Detail
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.1.5 Sarepta Therapeutics Recent Development
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Detail
11.2.2 PTC Therapeutics Business Overview
11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.2.5 PTC Therapeutics Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.3.5 Pfizer Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Italfarmaco
11.5.1 Italfarmaco Company Detail
11.5.2 Italfarmaco Business Overview
11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.5.5 Italfarmaco Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Detail
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
11.6.5 Santhera Pharmaceuticals Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2018-2023)
Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2024-2029)
Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2018-2023)
Table 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2024-2029)
Table 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2018-2023)
Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2024-2029)
Table 18. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Table 19. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Table 20. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
Table 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Table 22. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Headquarters and Area Served
Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 45. Sarepta Therapeutics Company Detail
Table 46. Sarepta Therapeutics Business Overview
Table 47. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 48. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Sarepta Therapeutics Recent Development
Table 50. PTC Therapeutics Company Detail
Table 51. PTC Therapeutics Business Overview
Table 52. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 53. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 54. PTC Therapeutics Recent Development
Table 55. Pfizer Company Detail
Table 56. Pfizer Business Overview
Table 57. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 58. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Pfizer Recent Development
Table 60. Bristol-Myers Squibb Company Detail
Table 61. Bristol-Myers Squibb Business Overview
Table 62. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 63. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Bristol-Myers Squibb Recent Development
Table 65. Italfarmaco Company Detail
Table 66. Italfarmaco Business Overview
Table 67. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 68. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Italfarmaco Recent Development
Table 70. Santhera Pharmaceuticals Company Detail
Table 71. Santhera Pharmaceuticals Business Overview
Table 72. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 73. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Santhera Pharmaceuticals Recent Development
Table 75. Sarepta Therapeutics Company Information
Table 76. Sarepta Therapeutics Business Overview
Table 77. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million)
Table 78. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 79. Sarepta Therapeutics Recent Development
Table 80. PTC Therapeutics Company Information
Table 81. PTC Therapeutics Business Overview
Table 82. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million)
Table 83. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 84. PTC Therapeutics Recent Development
Table 85. Pfizer Company Information
Table 86. Pfizer Business Overview
Table 87. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million)
Table 88. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 89. Pfizer Recent Development
Table 90. Bristol-Myers Squibb Company Information
Table 91. Bristol-Myers Squibb Business Overview
Table 92. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million)
Table 93. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 94. Bristol-Myers Squibb Recent Development
Table 95. Italfarmaco Company Information
Table 96. Italfarmaco Business Overview
Table 97. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million)
Table 98. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 99. Italfarmaco Recent Development
Table 100. Santhera Pharmaceuticals Company Information
Table 101. Santhera Pharmaceuticals Business Overview
Table 102. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million)
Table 103. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 104. Santhera Pharmaceuticals Recent Development
Table 105. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Picture
Figure 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2022 VS 2029
Figure 7. Exondys Product Picture
Figure 8. Emflaza Product Picture
Figure 9. Translarna Product Picture
Figure 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2029) & (US$ Million)
Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2022 VS 2029
Figure 12. Hospitals Product Picture
Figure 13. Clinics Product Picture
Figure 14. Home Care Product Picture
Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2022 VS 2029
Figure 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2022
Figure 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players, Date of Enter into This Industry
Figure 20. Global Top 5 and 10 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share by Revenue in 2022
Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 22. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2018-2029)
Figure 24. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2018-2029)
Figure 28. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2018-2029)
Figure 36. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2018-2029)
Figure 44. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2018-2029)
Figure 48. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023)
Figure 52. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023)
Figure 53. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023)
Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023)
Figure 55. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023)
Figure 56. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2018-2023)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings